echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Shanghai Pharmaceuticals Rosuvastatin Calcium Tablets Approved for Production

    Shanghai Pharmaceuticals Rosuvastatin Calcium Tablets Approved for Production

    • Last Update: 2021-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the 17th, Shanghai Pharmaceuticals issued an announcement stating that rosuvastatin calcium tablets of Shanghai Pharmaceutical Xinyi, a wholly-owned subsidiary of Shanghai Pharmaceuticals, received the "Drug Registration Certificate" issued by the State Food and Drug Administration, and the drug was approved for production


    Rosuvastatin calcium tablets are mainly used for the treatment of primary hypercholesterolemia (type IIa, including heterozygous familial) that cannot properly control dyslipidemia after diet control and other non-drug treatments (such as exercise therapy, weight loss) Hypercholesterolemia) or mixed dyslipidemia (type IIb)


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.